Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion system
Open Access
- 2 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 27 (1), 1-9
- https://doi.org/10.1186/s12929-020-00690-7
Abstract
A lung transplant is the last resort treatment for many patients with advanced lung disease. The majority of donated lungs come from donors following brain death (BD). The endothelin axis is upregulated in the blood and lung of the donor after BD resulting in systemic inflammation, lung damage and poor lung graft outcomes in the recipient. Tezosentan (endothelin receptor blocker) improves the pulmonary haemodynamic profile; however, it induces adverse effects on other organs at high doses. Application of ex vivo lung perfusion (EVLP) allows the development of organ-specific hormone resuscitation, to maximise and optimise the donor pool. Therefore, we investigate whether the combination of EVLP and tezosentan administration could improve the quality of donor lungs in a clinically relevant 6-h ovine model of brain stem death (BSD). After 6 h of BSD, lungs obtained from 12 sheep were divided into two groups, control and tezosentan-treated group, and cannulated for EVLP. The lungs were monitored for 6 h and lung perfusate and tissue samples were processed and analysed. Blood gas variables were measured in perfusate samples as well as total proteins and pro-inflammatory biomarkers, IL-6 and IL-8. Lung tissues were collected at the end of EVLP experiments for histology analysis and wet-dry weight ratio (a measure of oedema). Our results showed a significant improvement in gas exchange [elevated partial pressure of oxygen (P = 0.02) and reduced partial pressure of carbon dioxide (P = 0.03)] in tezosentan-treated lungs compared to controls. However, the lungs hematoxylin–eosin staining histology results showed minimum lung injuries and there was no difference between both control and tezosentan-treated lungs. Similarly, IL-6 and IL-8 levels in lung perfusate showed no difference between control and tezosentan-treated lungs throughout the EVLP. Histological and tissue analysis showed a non-significant reduction in wet/dry weight ratio in tezosentan-treated lung tissues (P = 0.09) when compared to control. These data indicate that administration of tezosentan could improve pulmonary gas exchange during EVLP.Keywords
This publication has 69 references indexed in Scilit:
- Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an ex vivo lung perfusion system followed by transplantationJournal of Surgical Research, 2013
- Inflammatory Signalling Associated with Brain Dead Organ Donation: From Brain Injury to Brain Stem Death and Posttransplant Ischaemia Reperfusion InjuryJournal of Transplantation, 2013
- Ex Vivo Adenoviral Vector Gene Delivery Results in Decreased Vector-associated Inflammation Pre- and Post–lung Transplantation in the PigMolecular Therapy, 2012
- Adenosine A2A Agonist Improves Lung Function During Ex Vivo Lung PerfusionThe Annals of Thoracic Surgery, 2011
- Diagnosis of Brain DeathNeurology International, 2010
- Role of endothelin-1 in acute lung injuryTranslational Research, 2009
- Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB ReceptorAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Time-Dependent Changes in Donor Brain Death Related ProcessesAmerican Journal of Transplantation, 2006
- The Hemodynamic Mechanisms of Lung Injury and Systemic Inflammatory Response Following Brain Death in the Transplant DonorAmerican Journal of Transplantation, 2005
- Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant modelGene Therapy, 2004